Microbiota-Endometriosis Axis: An Immune-Endocrine Integration Model and Emerging Therapeutic Targets
A narrative review proposes an integrative model in which gut, vaginal, and endometrial microbiota dysbiosis modulates immune and estrogenic pathways in endometriosis.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
The abstract describes how microbial β-glucuronidase activity and enterohepatic estrogen recirculation may sustain the hyperestrogenic environment of endometriosis. Multiple microbiota compartments are implicated in intestinal barrier disruption, pro-inflammatory signaling, and immune dysregulation. Current pharmacological treatments are characterized as limited, motivating exploration of upstream therapeutic targets.
How it was done
This is a narrative/integrative review with no primary data collection. The abstract does not report systematic search criteria, databases used, or PRISMA compliance.
Risk of bias
Narrative reviews are prone to literature selection bias and do not quantify effect sizes. No information on study quality assessment or inclusion criteria is available from the abstract.
What this study does NOT prove
The review does not establish causality between dysbiosis and endometriosis, nor does it demonstrate efficacy of any microbiota-based intervention.
In clinical practice
No clinical recommendation can be derived from this review alone. Microbiota-targeted interventions for endometriosis lack support from robust clinical trials.
Limitations
Narrative reviews are prone to literature selection bias and do not quantify effect sizes. No information on study quality assessment or inclusion criteria is available from the abstract.
Technical appendix
Version history
- 1.0 · 2026-08-23 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.